Aché Laboratórios Farmacêuticos
As of the edition of 20 October 2026, Aché Laboratórios Farmacêuticos runs 19 drugs, 19 of them marketed; it is on route A at 0 targets and on route B at 13 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 19 |
| Total | 19 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Filgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Lidocaine | none listed | 2 |
| Rosuvastatin | none listed | 3 |
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Pregabalin | none listed | 2 |
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Pegfilgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Aripiprazole | none listed | 3 |
| Losartan | none listed | 1 |
| Levetiracetam | none listed | 3 |
| Enoxaparin sodium | none listed | 3 |
| Famotidine | none listed | 2 |
| Acyclovir | none listed | 0 |
| Desloratadine | none listed | 3 |
| Domperidone | none listed | 1 |
| Guaifenesin | none listed | 0 |
| Bilastine | none listed | 2 |
| Nimesulide | none listed | 2 |
| Desonide | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 13 targets.
All 13 rows on route A or B
In the product13 company-target rows on route A or B; 10 are not shown here, and no score is.
See all 13 targets where Aché Laboratórios Farmacêuticos needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.